Senores Pharmaceuticals Ltd Stock Price Today (NSE: SENORES)

Senores Pharmaceuticals Ltd

1033.5034.30 (3.21%)
Market Closed

Fundamental Score

...

Senores Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Senores Pharmaceuticals Ltd share price today is 1033.50, down 3.21% on NSE/BSE as of 19 June 2026. Senores Pharmaceuticals Ltd (SENORES) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 3.72K (Cr). The 52-week high for SENORES share price is 1194.40 and the 52-week low is 513.00. At a P/E ratio of 42.68x, SENORES is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 11.82% and a debt-to-equity ratio of 0.30.

Senores Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
1194.40
Low
877.55
Volume
6.0L
Change
+18.47%

Senores Pharmaceuticals Ltd share price chart: 18.47% return over the past month. 52-week high ₹1194.40, 52-week low ₹513.00.

Senores Pharmaceuticals Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
1065.001079.901020.301033.508.26L (Cr)
1042.301149.001032.201067.808.64L (Cr)
1128.901134.001099.801120.652.53L (Cr)
1113.351113.351113.351113.350.00 (Cr)
1146.001161.951107.001113.352.25L (Cr)
1150.151173.801141.001155.152.33L (Cr)
1116.451160.001115.351153.652.69L (Cr)
1112.601130.001093.151110.954.01L (Cr)
1095.001127.801095.001109.353.07L (Cr)
1051.401099.001044.301083.704.61L (Cr)

Senores Pharmaceuticals Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
1042.301149.001020.301033.50-0.84%
904.001194.40877.551120.65+23.97%
797.00947.70741.90899.20+12.82%
747.00801.40706.00759.60+1.69%
786.00849.40760.00764.90-2.68%
825.00876.50752.40787.95-4.49%
825.00849.10738.10822.20-0.34%
771.20832.00755.00823.70+6.81%
689.95790.00684.60771.20+11.78%
690.15751.20662.45688.10-0.30%
689.10737.85632.05690.15+0.15%
585.00719.00558.55688.90+17.76%

Returns & Performance

Poor

Return on Equity (ROE)

11.82%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

11.40%

Returns generated on total capital deployed

Oper. Profit Margin (5Y Avg)

N/A

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Senores Pharmaceuticals Ltd Valuation Check

Poor

Price to Earnings (P/E)

42.68x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.77x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

45.80%

% shares held by company founders/management

Poor

FII Holding

4.28%

% shares held by foreign institutional investors

Average

DII Holding

8.62%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

152.18%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

60.75%

Revenue growth vs same quarter last year

Revenue Growth (5-Year CAGR)

N/A

Compounded annual revenue growth over 5 years

EPS Growth (5-Year CAGR)

N/A

Earnings per share growth over 5 years

Net Profit Growth (5-Year CAGR)

N/A

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.30x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

5.77x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

N/A

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Senores Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of SENORES across key market metrics for learning purposes.

Positive Indicators

5 factors identified

Robust Profit Growth (152.18%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Strong Revenue Growth (60.75%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Conservative Debt Levels (D/E: 0.30)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (5.77x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

2 factors identified

Premium Valuation Risk (P/E: 42.68x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Senores Pharmaceuticals Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Senores Pharmaceuticals Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
38.9/100
1034
₹3717.89
42.7
Average
11.82%
Average
11.40%
Average
0.3
Excellent
0.00%
65.2/100
1844
₹433738.68
37.6
Average
16.86%
Good
20.21%
Excellent
0.1
Excellent
23.78%
Excellent
9.87%
Good
0.89%
67.9/100
6798
₹170445.88
68.6
Average
15.35%
Good
20.44%
Excellent
0.0
Excellent
10.41%
Good
11.65%
Good
0.47%
65.3/100
4538
₹126430.62
58.4
Average
26.52%
Excellent
27.05%
Excellent
0.3
Excellent
13.84%
Good
7.72%
Good
0.86%
Cipla Ltd...
CIPLA500087
59/100
1418
₹123059.76
22.6
Average
17.77%
Good
22.72%
Excellent
0.0
Excellent
28.68%
Excellent
9.97%
Good
0.85%
59.2/100
1319
₹105224.96
18.2
Average
17.96%
Good
22.69%
Excellent
0.2
Excellent
22.28%
Excellent
13.26%
Good
0.63%
Lupin Ltd...
LUPIN500257
66.7/100
2276
₹95148.15
22.0
Average
20.62%
Excellent
21.30%
Excellent
0.3
Excellent
54.88%
Excellent
8.11%
Good
0.58%
68.7/100
957
₹94253.78
18.7
Average
21.21%
Excellent
24.31%
Excellent
0.4
Excellent
25.92%
Excellent
10.27%
Good
1.17%
50.6/100
2420
₹92012.53
52.6
Average
14.68%
Average
15.98%
Good
0.6
Good
11.73%
Good
15.79%
Excellent
0.04%
28.8/100
1436
₹70798.69
20.7
Average
11.08%
Average
14.18%
Average
0.2
Excellent
3.87%
Average
6.55%
Good
0.33%
59.5/100
5452
₹67075.29
28.5
Average
19.39%
Good
20.38%
Excellent
0.2
Excellent
13.93%
Good
9.21%
Good
0.80%

Senores Pharmaceuticals Ltd PE Ratio History

Historical price-to-earnings ratio for SENORES — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 202516.12₹822.2051x
FY 20246.83₹568.6083.3x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Senores Pharmaceuticals Ltd Quarterly Performance

Latest quarterly metrics for SENORES — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

60.75%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

152.18%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

N/A

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

N/A

Compounded annual net profit growth over 5 years

Senores Pharmaceuticals Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for SENORES — calculated from daily price history

68RSI 14
Neutral — RSI 68

Momentum is balanced — neither overbought nor oversold.

SMA 50
890
▲ Price above SMA 50 — Short-term bullish
SMA 200
794
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
535K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Senores Pharmaceuticals Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Senores Pharmaceuticals Ltd (SENORES) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Senores Pharmaceuticals Ltd

About SENORES (Senores Pharmaceuticals Ltd)

Senores Pharmaceuticals Ltd is a global pharmaceutical company dedicated to advancing healthcare through the discovery, development, and commercialization of innovative therapies. ...With a strong emphasis on research and development, Senores Pharmaceuticals is committed to addressing unmet medical needs across a broad range of therapeutic areas. The company's mission is to improve patient outcomes and enhance the quality of life for individuals worldwide by providing access to safe, effective, and affordable medicines. Senores Pharmaceuticals operates with the highest ethical standards and a focus on sustainability, ensuring that its business practices are environmentally responsible and socially conscious. They strive to be a trusted partner for healthcare professionals and patients, offering comprehensive support and resources to optimize treatment outcomes. Driven by a passion for scientific excellence, Senores Pharmaceuticals invests heavily in cutting-edge technologies and strategic collaborations to accelerate the development of novel therapeutics. The company's robust pipeline includes a diverse portfolio of products in various stages of development, targeting diseases with significant unmet needs. Senores Pharmaceuticals is committed to bringing innovative solutions to market that transform the lives of patients. Their experienced team of scientists, clinicians, and business professionals work collaboratively to navigate the complex regulatory landscape and ensure the timely delivery of high-quality products to patients in need. Senores Pharmaceuticals is dedicated to fostering a culture of innovation, collaboration, and patient-centricity, where every employee is empowered to make a difference in the world. Senores Pharmaceuticals is focused on expanding its global reach and strengthening its presence in key markets. The company's commercial operations are supported by a dedicated sales and marketing team that is committed to providing healthcare professionals with the information and resources they need to make informed treatment decisions. Senores Pharmaceuticals has established a strong distribution network to ensure that its products are readily available to patients around the world. In addition to its own product portfolio, Senores Pharmaceuticals is actively seeking partnerships and licensing agreements to expand its offerings and address a wider range of medical needs. The company is dedicated to building long-term relationships with healthcare providers, payers, and patient advocacy groups to improve access to care and promote positive health outcomes.

Company Details

Symbol:SENORES
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Swapnil Jatinbhai Shah
MD & Director
Mr. Deval Rajnikant Shah
Whole-Time Director & CFO
Mr. Chetan Bipinchandra Shah
Whole-Time Director & COO

SENORES Share Price: Frequently Asked Questions

What is the current share price of Senores Pharmaceuticals Ltd?

Senores Pharmaceuticals Ltd (SENORES) trades at ₹1033.50 on NSE and BSE. Market cap ₹3.72K (Cr). Educational data only.

What is the P/E ratio of Senores Pharmaceuticals Ltd?

Senores Pharmaceuticals Ltd has a P/E of 42.68x vs industry average 31.77x.

What is the Bull Run score for Senores Pharmaceuticals Ltd?

Senores Pharmaceuticals Ltd has a Bull Run score of 38.9/100 based on 25+ financial parameters.

Does Senores Pharmaceuticals Ltd pay dividends?

Senores Pharmaceuticals Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Senores Pharmaceuticals Ltd?

Senores Pharmaceuticals Ltd has ROE of 11.82%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Senores Pharmaceuticals Ltd?

Senores Pharmaceuticals Ltd has debt-to-equity of 0.30.

Is Senores Pharmaceuticals Ltd a good investment?

Bull Run gives Senores Pharmaceuticals Ltd a score of 38.9/100. This is not investment advice — consult a SEBI-registered advisor.